Céline Féger

561 total citations
18 papers, 425 citations indexed

About

Céline Féger is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Céline Féger has authored 18 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 8 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Céline Féger's work include Antimicrobial Resistance in Staphylococcus (8 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Clostridium difficile and Clostridium perfringens research (4 papers). Céline Féger is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (8 papers), Bacterial Identification and Susceptibility Testing (5 papers) and Clostridium difficile and Clostridium perfringens research (4 papers). Céline Féger collaborates with scholars based in France, Canada and Germany. Céline Féger's co-authors include Roland Leclercq, Michael J. Dowzicky, George H. Talbot, Virginie Zarrouk, Bülent Bozdoğan, B. Fantin, Philippe Prokocimer, Jean de Gunzburg, Antoine Andremont and Annie Ducher and has published in prestigious journals such as Clinical Cancer Research, The American Journal of Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Céline Féger

18 papers receiving 402 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Céline Féger France	13	286	142	125	120	75	18	425
Michelle Barron United States	11	437 1.5×	294 2.1×	81 0.6×	113 0.9×	61 0.8×	24	575
Toshiki Kajihara Japan	13	139 0.5×	127 0.9×	89 0.7×	85 0.7×	127 1.7×	34	454
Flaminia Olearo Germany	12	234 0.8×	118 0.8×	83 0.7×	64 0.5×	96 1.3×	32	407
Banu Bayraktar Türkiye	14	156 0.5×	135 1.0×	78 0.6×	60 0.5×	127 1.7×	42	428
Adriana Manzur Spain	14	270 0.9×	265 1.9×	118 0.9×	94 0.8×	125 1.7×	22	566
Oriol Gasch Spain	13	293 1.0×	180 1.3×	184 1.5×	66 0.6×	42 0.6×	39	446
Francesca Crea Italy	13	220 0.8×	213 1.5×	158 1.3×	88 0.7×	68 0.9×	21	612
Wendi Jiang China	7	232 0.8×	282 2.0×	68 0.5×	91 0.8×	44 0.6×	12	588
Paolo Carfagna Italy	11	219 0.8×	181 1.3×	74 0.6×	33 0.3×	39 0.5×	24	331
Raman Sardana India	9	402 1.4×	292 2.1×	87 0.7×	91 0.8×	35 0.5×	34	553

Countries citing papers authored by Céline Féger

Since Specialization

Citations

This map shows the geographic impact of Céline Féger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Féger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Féger more than expected).

Fields of papers citing papers by Céline Féger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Féger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Féger. The network helps show where Céline Féger may publish in the future.

Co-authorship network of co-authors of Céline Féger

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Féger. A scholar is included among the top collaborators of Céline Féger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Féger. Céline Féger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

1.

Messaoudene, Meriem, Nathalie Saint-Lu, Stéphanie Ferreira, et al.. (2022). 1306 Prevention of antibiotic-induced dysbiosis in human volunteers by DAV132 and preservation of responsiveness to anti-PD-1 therapy demonstrated by transplantation of human feces into tumor-bearing mice. Regular and Young Investigator Award Abstracts. A1356–A1357. 1 indexed citations

2.

Dupuis, Claire, Juliette Patrier, Céline Féger, et al.. (2021). Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs. Critical Care. 25(1). 24–24. 20 indexed citations

3.

Féger, Céline, et al.. (2021). The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia. BMC Infectious Diseases. 21(1). 949–949. 26 indexed citations

4.

Vehreschild, Maria J. G. T., Annie Ducher, Thomas Louie, et al.. (2021). An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones. Journal of Antimicrobial Chemotherapy. 77(4). 1155–1165. 25 indexed citations

5.

Varastet, Marina, Céline Féger, Tanguy Corbel, et al.. (2021). A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(8). 908–917. 2 indexed citations

6.

Ducher, Annie, Maria J. G. T. Vehreschild, Thomas Louie, et al.. (2020). LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD). Open Forum Infectious Diseases. 7(Supplement_1). S845–S846. 2 indexed citations

7.

Gunzburg, Jean de, Annie Ducher, Christiane Modeß, et al.. (2014). Targeted adsorption of molecules in the colon with the novel adsorbent‐based Medicinal Product, DAV132: A proof of concept study in healthy subjects. The Journal of Clinical Pharmacology. 55(1). 10–16. 59 indexed citations

8.

Timsit, Jean‐François, Yohann Dubois, Jean‐Ralph Zahar, et al.. (2011). Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Critical Care. 15(2). R112–R112. 16 indexed citations

9.

Kuppens, I. E. L. M., Éric Dansin, Henk Boot, et al.. (2006). Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12(12). 3774–3781. 11 indexed citations

10.

Saleh‐Mghir, Azzam, Claudette Muller‐Serieys, Laurent Massias, et al.. (2002). Combination of Quinupristin-Dalfopristin (Synercid) and Rifampin Is Highly Synergistic in Experimental Staphylococcus aureus Joint Prosthesis Infection. Antimicrobial Agents and Chemotherapy. 46(4). 1122–1124. 35 indexed citations

11.

Malbruny, Brigitte, A. Canu, Bülent Bozdoğan, et al.. (2002). Resistance to Quinupristin-Dalfopristin Due to Mutation of L22 Ribosomal Protein inStaphylococcus aureus. Antimicrobial Agents and Chemotherapy. 46(7). 2200–2207. 56 indexed citations

12.

Zarrouk, Virginie, Bülent Bozdoğan, Roland Leclercq, et al.. (2001). Activities of the Combination of Quinupristin-Dalfopristin with Rifampin In Vitro and in Experimental Endocarditis Due to Staphylococcus aureus Strains with Various Phenotypes of Resistance to Macrolide-Lincosamide-Streptogramin Antibiotics. Antimicrobial Agents and Chemotherapy. 45(6). 1941–1941. 1 indexed citations

13.

Zarrouk, Virginie, Bülent Bozdoğan, Roland Leclercq, et al.. (2001). Activities of the Combination of Quinupristin-Dalfopristin with Rifampin In Vitro and in Experimental Endocarditis Due to Staphylococcus aureus Strains with Various Phenotypes of Resistance to Macrolide-Lincosamide-Streptogramin Antibiotics. Antimicrobial Agents and Chemotherapy. 45(4). 1244–1248. 27 indexed citations

14.

Auckenthaler, R, et al.. (2000). In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci. Clinical Microbiology and Infection. 6(11). 608–612. 15 indexed citations

15.

Dowzicky, Michael J., George H. Talbot, Céline Féger, et al.. (2000). Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid®) during a worldwide clinical program. Diagnostic Microbiology and Infectious Disease. 37(1). 57–62. 41 indexed citations

16.

Vouillamoz, Jacques, et al.. (2000). Quinupristin-Dalfopristin Combined with β-Lactams for Treatment of Experimental Endocarditis Due to Staphylococcus aureus Constitutively Resistant to Macrolide-Lincosamide-Streptogramin B Antibiotics. Antimicrobial Agents and Chemotherapy. 44(7). 1789–1795. 34 indexed citations

17.

Dowzicky, Michael J., et al.. (1999). Quinupristin/dalfopristin: A novel selective-spectrum antibiotic for the treatment of multi-resistant and other gram-positive pathogens. Clinical Microbiology Newsletter. 21(13). 103–112. 18 indexed citations

18.

Dowzicky, Michael J., et al.. (1998). Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. The American Journal of Medicine. 104(5). 34S–42S. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact